Full text is available at the source.
Correlation between O6-methylguanine-DNA methyltransferase and survival in elderly patients with glioblastoma treated with radiotherapy plus concomitant and adjuvant temozolomide
Link between DNA repair enzyme levels and survival in older glioblastoma patients treated with radiation and chemotherapy
AI simplified
Abstract
Median overall survival (OS) was 15.3 months for patients with methylated MGMT promoters, compared to 10.2 months for those with unmethylated promoters.
- Epigenetic silencing of the MGMT gene through promoter methylation is linked to improved overall survival (OS) and progression-free survival (PFS) in elderly glioblastoma multiforme (GBM) patients.
- In a study of 83 patients aged 70 and older, 50.6% had methylated MGMT promoters.
- Median PFS was 10.5 months for patients with methylated tumors, while it was 5.5 months for those with unmethylated tumors.
- MGMT methylation status was identified as the strongest independent prognostic factor for OS and PFS.
- Statistical analyses indicated significant differences in survival outcomes based on MGMT methylation status.
AI simplified